Processa Pharmaceuticals, Inc. (PCSA) stock
PCSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$1.56−0.13 (-7.69%)
Close on Nov 20, 2026Market cap $4.36MP/E –Yield –
Processa Pharmaceuticals net income
Net income is the profit left for shareholders after every expense, interest and tax.
Processa Pharmaceuticals's net income for the twelve months ending Dec 31, 2025 was -$13.56M. For fiscal 2025 it was -$13.56M. The highest annual figure on record is -$1.86M in fiscal 2017.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.56M | – |
| FY2024 | Dec 31, 2024 | -$11.85M | – |
| FY2023 | Dec 31, 2023 | -$11.12M | – |
| FY2022 | Dec 31, 2022 | -$27.42M | – |
| FY2021 | Dec 31, 2021 | -$11.43M | – |
| FY2020 | Dec 31, 2020 | -$14.41M | – |
| FY2019 | Dec 31, 2019 | -$3.36M | – |
| FY2018 | Dec 31, 2018 | -$3.77M | – |
| FY2017 | Dec 31, 2017 | -$1.86M | – |
| FY2016 | Dec 31, 2016 | -$1.92M | – |
| FY2015 | Dec 31, 2015 | -$3.35M | – |
| FY2014 | Dec 31, 2014 | -$4.53M | – |
| FY2013 | Dec 31, 2013 | -$3.07M | – |
| FY2012 | Dec 31, 2012 | -$2.44M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.38M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.36M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.83M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.73M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.38M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.01M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.73M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.40M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.08M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.61M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.02M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.01M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.16M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.23M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.18M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.99M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.16M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.10M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.73M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.07M | – |
| Q2 FY2020 | Jun 30, 2020 | -$733.41K | – |
| Q1 FY2020 | Mar 31, 2020 | -$874.34K | – |
| Q4 FY2019 | Dec 31, 2019 | -$774.44K | – |
| Q3 FY2019 | Sep 30, 2019 | -$863.52K | – |
| Q2 FY2019 | Jun 30, 2019 | -$969.08K | – |
| Q1 FY2019 | Mar 31, 2019 | -$750.83K | – |
| Q4 FY2018 | Dec 31, 2018 | -$609.17K | – |
| Q3 FY2018 | Sep 30, 2018 | -$852.82K | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.21M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.10M | – |
| Q4 FY2017 | Dec 31, 2017 | -$633.86K | – |
| Q1 FY2017 | Mar 31, 2017 | -$232.44K | – |
| Q4 FY2016 | Dec 31, 2016 | -$234.34K | – |
| Q3 FY2016 | Sep 30, 2016 | -$827.37K | – |
| Q2 FY2016 | Jun 30, 2016 | -$574.41K | – |
| Q1 FY2016 | Mar 31, 2016 | -$280.95K | – |
See a number that looks wrong?